<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922008</url>
  </required_header>
  <id_info>
    <org_study_id>SCHBCC-N034</org_study_id>
    <nct_id>NCT04922008</nct_id>
  </id_info>
  <brief_title>Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)</brief_title>
  <official_title>An Open-label, Phase II Study Evaluating the Efficacy and Safety of Trastuzumab Combined With Oral Chemotherapy in Patients With HER-2 Positive Stage I Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, phase II study evaluating the efficacy and safety of trastuzumab&#xD;
      combined with oral chemotherapy (capecitabine or vinorelbine) in patients with HER-2 positive&#xD;
      stage I breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iDFS</measure>
    <time_frame>5 years</time_frame>
    <description>iDFS invasive disease-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DDFS</measure>
    <time_frame>5 years</time_frame>
    <description>distant disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IRIS-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IRIS-D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine and trastuzumab</intervention_name>
    <description>In IRIS-C cohort, patients who met the inclusion criteria(ER and PR&lt;10%, T≤2cm or ER and/or PR ≥10% 1cm&lt;T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.</description>
    <arm_group_label>IRIS-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine and trastuzumab</intervention_name>
    <description>In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR&lt;10%, T≤2cm or ER and/or PR ≥10% 1cm&lt;T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.</description>
    <arm_group_label>IRIS-D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females 18-70 years old;&#xD;
&#xD;
          -  Pathological confirmed of stage I breast cancer: histologically confirmed that the&#xD;
             longest diameter of invasive cancer is no more than 2cm and the lymph node is negative&#xD;
             (N0);&#xD;
&#xD;
          -  If a patient is HR negative(ER/PR&lt;10%), the longest diameter of invasive cancer could&#xD;
             not exceed 2cm; while if a patient is HR positive(ER and/or PR ≥10%）,the longest&#xD;
             diameter of invasive cancer is greater than 1cm and no more than 2cm;&#xD;
&#xD;
          -  The pathological type of immunohistochemistry must meet the following conditions:&#xD;
             HER-2 (3+) or HER-2 (0-2 +) with FISH detection is amplified;&#xD;
&#xD;
          -  For patients with invasive lesions on both sides, if both lesions are HER-2 positive&#xD;
             and meet the tumor size requirements, then can be enrolled;&#xD;
&#xD;
          -  Has adequate organ function meeting the following criteria: (1) adequate bone marrow&#xD;
             function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute&#xD;
             neutrophil count ≥ 1.5 x 109 /L; platelet count ≥ 100 * 109 /L; (2)adequate liver and&#xD;
             kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN),&#xD;
             Aspartate Aminotransferase (AST)&#xD;
&#xD;
             ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum creatinine ≤ 1×ULN#and with endogenous&#xD;
             creatinine clearance rate of &gt;50 ml/min (Cockcroft-Gault formula);&#xD;
&#xD;
          -  LVEF&gt;50%;&#xD;
&#xD;
          -  The patient voluntarily joined the study, signed the informed consent form, had good&#xD;
             compliance, and cooperated with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy&#xD;
             or endocrine therapy;&#xD;
&#xD;
          -  Has previous history of additional malignancy, with the exception of adequately&#xD;
             treated basal cell carcinoma and cervical carcinoma in situ;&#xD;
&#xD;
          -  Has metastic (Stage 4) breast cancer;&#xD;
&#xD;
          -  Pregnant or breast feeding women, or women of childbearing age who cannot practice&#xD;
             effective contraceptives;&#xD;
&#xD;
          -  Patients participating in other clinical trials at the same time;&#xD;
&#xD;
          -  Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left&#xD;
             ventricular ejection fraction (LVEF) &lt; 50% (cardiac ultrasound); severe cardio&#xD;
             cerebral vascular disease within the 6 months previous of randomization (such as&#xD;
             unstable angina, chronic heart failure, uncontrolled hypertension with blood&#xD;
             pressure&gt;150/90mmHg, myocardial infarction, or cerebral blood vessel); diabetic&#xD;
             patients with poor blood glucose control; patients with severe hypertension;&#xD;
&#xD;
          -  Has severe or uncontrolled infection;&#xD;
&#xD;
          -  Has a history of psychotropic substance abuse and were unable to abandon drug habits,&#xD;
             or those with history of mental disorders;&#xD;
&#xD;
          -  The researchers considered patients to be unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

